Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh
Hussain et al.
, Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh
, International Journal of Molecular and Immuno Oncology, doi:10.25259/IJMIO_30_2020 (Preprint)
Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again.
Hussain et al., 11 Dec 2020, preprint, 3 authors.
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/346639384
Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A
positive experience in Bangladesh
Article in International Journal of Molecular and Immuno Oncology · December 2020
3 authors, including:
Square Hospitals Limited
Vancouver General Hospital
2 PUBLICATIONS 6 CITATIONS
20 PUBLICATIONS 20 CITATIONS
Some of the authors of this publication are also working on these related projects:
Chemotherapy View project
Head and Neck Cancer View project
All content following this page was uploaded by Md Shuayb on 04 December 2020.
The user has requested enhancement of the
International Journal of Molecular &
Article in Press
Outcome of ivermectin and doxycycline in cancer
patients with COVID-19: A positive experience in
Syed Md Akram Hussain1, Md Shuayb2, Mahmudur Rahman3
Department of Oncology, Square Hospitals, West Panthapath, Dhaka, Bangladesh, 2Vancouver Prostate Centre, Vancouver General Hospital, The University of
British Columbia, Vancouver, Canada, 3Emerging Infections Program, IDD, International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh.
Syed Md Akram Hussain,
Department of Oncology,
West Panthapath, Dhaka,
Received : 17 September 2020
Accepted : 20 October 2020
Quick Response Code:
The world, today, is facing an immense challenge with the outbreak of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection known as coronavirus disease 2019
(COVID-19). Bangladesh is the 16th ranked pandemic part of the world with 244,020 cases
diagnosed and 3234 deaths to date. At present, no FDA approved remedies are available to defeat
this deadly disease. Ivermectin, an antiparasitic drug, has been found to inhibit the replication
of the SARS-CoV-2 virus in vitro. When combined with doxycycline, an antibacterial drug,
ivermectin showed encouraging activity in reducing viral load, possible molecular mechanisms
of which have been proposed very recently.[3,4] Globally, a number of clinical trials are going on
to explore the activity of these two widely used FDA approved drugs as a potential therapy for
Although no systematic data are available, several studies including the European Society for
Medical Oncology and the National Institute for Health and Care Excellence guidelines have
reported that cancer patients are more vulnerable to develop COVID-19 infection. We sought
to investigate the effectiveness of ivermectin plus doxycycline in COVID-19-positive cancer
patients in a tertiary care cancer center of Dhaka city in Bangladesh.
This is a case series conducted at the Oncology and Radiotherapy Centre of Square Hospital,
Bangladesh. A total of eight patients were treated with ivermectin and doxycycline combination
to date, who met the eligibility criteria. The primary outcome was treatment response and the
secondary outcome was treatment-related toxicity. Inclusion criteria included in this study were
patients with any stage of solid malignancies or lymphoma proved by pathology; active disease
being treated with chemotherapy and/or..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.